Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NMT1 | P30419 | 6/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16508907 | 0.85 | TSHR (0.48) | TSHRNPY5RMAPTNMT1LMNA | |
| SCHEMBL14149159 | 0.77 | TSHR (0.53) | TSHRMAPTNMT1LMNAHTT | |
| SCHEMBL6097407 | 0.72 | MCL1 (0.45) | TSHRNMT1L3MBTL1 | |
| SCHEMBL1472224 | 0.71 | POLB (0.49) | NMT1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1472702 | 0.71 | GAA (0.43) | NMT1SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL14468543 | 0.71 | ALDH1A1 (0.48) | TSHRMAPTNMT1LMNAHTT | |
| SCHEMBL8232738 | 0.70 | TSHR (0.45) | TSHRMAPTNMT1SMN1; SMN2ALDH1A1 | |
| SCHEMBL16508903 | 0.69 | HTR6 (0.46) | TSHRNMT1LMNAHTTSMN1; SMN2 | |
| SCHEMBL3376273 | 0.69 | TSHR (0.44) | TSHRMAPTNMT1SMN1; SMN2ALDH1A1 | |
| SCHEMBL347771 | 0.69 | TSHR (0.44) | TSHRMAPTNMT1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214817-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | MARYANOFF BRUCE E (US) | 2012-08-23 | — | — | US | claimed |
| US-8193191-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-06-05 | — | — | US | claimed |
| EP-1993554-B1 | UROTENSIN II RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-11-23 | — | — | EP | claimed |
| US-20110136824-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | MARYANOFF BRUCE E | 2011-06-09 | — | — | US | claimed |
| US-7915260-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-03-29 | — | — | US | claimed |
| US-20070191391-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | US | claimed |
| US-8536174-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-17 | — | — | US | disclosed |
| US-20120214817-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | MARYANOFF BRUCE E (US) | 2012-08-23 | — | — | US | disclosed |
| US-8193191-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-06-05 | — | — | US | disclosed |
| EP-1993554-B1 | UROTENSIN II RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-11-23 | — | — | EP | disclosed |
| US-20110136824-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | MARYANOFF BRUCE E | 2011-06-09 | — | — | US | disclosed |
| US-7915260-B2 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-03-29 | — | — | US | disclosed |
| EP-1993554-A2 | UROTENSIN II RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2008-11-26 | — | — | EP | disclosed |
| US-20070191391-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | US | disclosed |
| WO-2007081995-A2 | UROTENSIN II RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214817-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, PLAUR, BDKRB2 | TSHR 510/4885NPY5R 247/4885MAPT 2181/4885 |
| US-20070191391-A1 | Urotensin II receptor antagonists | UTS2R, PLAUR, BDKRB2 | TSHR 510/4885NPY5R 247/4885MAPT 2181/4885 |
| US-20110136824-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, PLAUR, BDKRB2 | TSHR 510/4885NPY5R 247/4885MAPT 2181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.